Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
40.8M
-
Shares change
-
+4.78M
-
Total reported value, excl. options
-
$1.15B
-
Value change
-
+$134M
-
Number of buys
-
50
-
Number of sells
-
-18
-
Price
-
$28.13
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q4 2020
83 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q4 2020.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.8M shares
of 120M outstanding shares and own 33.98% of the company stock.
Largest 10 shareholders include FRAZIER MANAGEMENT LLC (10.5M shares), FMR LLC (6.55M shares), ORBIMED ADVISORS LLC (6.07M shares), Bain Capital Life Sciences Investors, LLC (3.98M shares), BlackRock Inc. (2.9M shares), RA CAPITAL MANAGEMENT, L.P. (1.17M shares), VANGUARD GROUP INC (1.09M shares), Point72 Asset Management, L.P. (875K shares), Vivo Capital, LLC (867K shares), and STATE STREET CORP (839K shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.